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Abstract
Kaposi’s Sarcoma (KS), the most common tumor of AIDS patients, is a highly vascularized tumor supporting large amounts
of angiogenesis. The main cell type of KS tumors is the spindle cell, a cell of endothelial origin, the primary cell type involved
in angiogenesis. Kaposi’s Sarcoma-associated herpesvirus (KSHV) is the etiologic agent of KS and is likely involved in both
tumor formation and the induction of angiogenesis. Integrins, and specifically integrin aVb3, have known roles in both
tumor induction and angiogenesis. aVb3 is also important for KSHV infection as it has been shown to be involved in KSHV
entry into cells. We found that during latent infection of endothelial cells KSHV induces the expression of integrin b3 leading
to increased surface levels of aVb3. Signaling molecules downstream of integrins, including FAK and Src, are activated
during viral latency. Integrin activation by KSHV is necessary for the KSHV-associated upregulation of a number of
angiogenic phenotypes during latent infection including adhesion and motility. Additionally, KSHV-infected cells become
more reliant on aVb3 for capillary like formation in three dimensional culture. KSHV induction of integrin b3, leading to
induction of angiogenic and cancer cell phenotypes during latency, is likely to be important for KS tumor formation and
potentially provides a novel target for treating KS tumors.
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Introduction
Kaposi’s sarcoma-associated herpesvirus (KSHV), a gamma
herpesvirus, is the etiological agent for Kaposi’s sarcoma (KS). KS
is the most common tumor in AIDS patients world-wide, and is
the most commonly reported tumor in parts of central Africa [1,2].
KS tumors are highly vascularized, with abnormal, leaky
vasculature, and excess inflammation and edema. The histopa-
thology of KS tumors supports a role for angiogenesis in tumor
formation. The primary cell type of KS lesions are spindle-shaped
endothelium-derived cells aptly named spindle cells. Nearly all
spindle cells support latent KSHV infection, although a low
percentage of cells undergoing lytic reactivation are always present
[3].
KSHV can infect many types of cells in culture including
endothelial cells [4,5]. KSHV infection of endothelial cells in
culture leads to predominantly latent infection with a similar low
percentage of cells undergoing lytic replication as in the KS tumor
[4,6]. KSHV infection of endothelial cells can promote angiogen-
esis related phenotypes, including increased stability of tubules
formed by macrovascular endothelial cells, induction of angio-
genesis and capillary morphogenesis in low growth factor
conditions, and enhanced migration and invasion [7–11].
Furthermore, KSHV infection can induce increased expression
and secretion of signaling factors involved in angiogenesis, such as
vascular endothelial growth factor (VEGF). Both VEGF-A and –C
are expressed by KSHV-infected endothelial cells [12,13].
Interestingly, KSHV infection promotes the upregulation of both
VEGF receptor 1, a blood vasculature marker, and VEGF
receptor 3, a marker for lymphatic endothelium [13–17]. The
upregulation of both VEGF receptors suggests KSHV-infected
cells are more sensitive to the growth and migratory effects of
VEGF than the surrounding uninfected endothelium. KSHV
infection also leads to upregulation of other molecules with
important roles in the regulation of angiogenesis. KSHV-induced
expression of cyclooxygenase-2 (COX-2) as well as angiogenin was
shown to be important for the maintenance of latency, as well as
inflammatory cytokine expression and capillary morphogenesis
[18]. KSHV infection of endothelial cells upregulates several
members of the angiopoietin family of growth factors, including
angiopoietin-2 and angiopoietin-like 4, which are involved in
regulating angiogenic remodeling and vessel stabilization [19-21].
In addition to secretion of growth factors, KSHV infection
promotes disruption of adherens junctions, allowing for increased
vascular permeability and invasion [22–25]. Furthermore, there
have been several studies examining the role of other molecules
and signaling pathways which have been implicated in KSHV-
induced angiogenesis [26–34].
Several KSHV genes have been shown to regulate expression of
genes involved in angiogenesis. For example, both vIRF3 and the
glycoprotein K1 promote VEGF expression [35,36]. Other genes
were found to have angiogenic chemoattractant properties, such as
the viral homologs to macrophage inflammatory proteins (vMIPs
I–III; [37,38]). The viral G-protein coupled receptor (vGPCR) is a
constitutively active signaling receptor that has been linked to a
variety of angiogenic signaling pathways [21,39–44]. However,
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during lytic replication and they have not been shown to be
necessary for the induction of angiogenic phenotypes in the
context of viral infection. Since only a small percentage of the
infected cells undergo lytic replication, it is unknown if these
proteins are sufficient to promote an angiogenic phenotype in the
more abundant latently infected endothelial cells.
During latency in endothelial cells, only five viral genes are
expressed, including the latency-associated nuclear antigen
(LANA-1). LANA-1 has been shown to play a role in a host of
processes including maintenance of the viral genome and host cell
survival (reviewed in [45]). In addition to these functions, LANA-1
may play several roles in promoting angiogenesis. Expression of
LANA-1 in endothelial cells induces upregulation of angiogenin,
which may aid in induction of angiogenesis by VEGF and basic
fibroblast growth factor [10]. Furthermore, LANA-1 interaction
with Daxx reduces its repression on Ets-1-dependent VEGF
receptor expression [46]. While it is apparent that KSHV genes
are capable of inducing angiogenic pathways, a better under-
standing of how viral infection alters the host cell to induce
angiogenesis is still needed.
Angiogenesis is a complex process that is tightly regulated by a
delicate balance of pro- and anti-angiogenic factors. However,
many pathogenic processes, such as tumor formation, shift this
balance to promote continual vascular growth. How the different
angiogenic signaling factors interact and are regulated is only
partly understood. Along with secreted cytokines and growth
factors, other signaling proteins such as integrins have been shown
to regulate endothelial cell activation and angiogenesis. Integrins
are cell surface proteins that link the extracellular matrix to the
cytoskeleton. They form dimers of a and b subunits that recognize
extracellular matrix (ECM) proteins and, upon ligand binding,
undergo conformational changes and recruit intracellular adaptor
and signaling molecules. Integrins can induce activation of focal
adhesion kinase (FAK) leading to activation of Src kinase. Integrin
signaling complexes play a role in a number of cellular processes
such as adhesion to the ECM, migration, and cell survival during
suspension, all of which are essential functions for endothelial cells
during the process of angiogenesis (reviewed in [47–49]). In
particular, aVb3 integrin has been shown to be upregulated in the
vasculature associated with a number of tumor types and has been
linked to regulation of angiogenesis [50–52]. Antagonists of
integrin aVb3 inhibit tumor angiogenesis and tumor growth in a
variety of animal models of cancer [52–55]. Interestingly, aVb3
integrin is a receptor for several viruses, including KSHV [56].
KSHV glycoprotein B (gB) can associate with integrins on the cell
surface leading to increased signaling, adhesion, and to cytoskel-
etal rearrangements. However, previous studies have not exam-
ined the role of integrins during latent KSHV infection.
We have identified a role for integrin b3 during latent infection
of KSHV in endothelial cells. Infected cells upregulate integrin b3
expression leading to increased cell surface aVb3. Latently
infected endothelial cells become more adherent to integrin
ligands fibronectin and vitronectin, and are also more migratory
than mock-infected cells. These induced phenotypes require
RGD-binding integrins, specifically integrin b3. Interestingly,
although both uninfected and infected cells organize in three-
dimensional culture, infected cells are more sensitive to inhibitors
of integrin b3 and its downstream signaling molecules, such as Src
kinase. This suggests that during latent KSHV infection there is a
shift in endothelial cell signaling that results in a more angiogenic
phenotype dependent on aVb3.
Results
Latent KSHV infection upregulates integrin b3 expression
Our microarray analysis of mock- and KSHV-infected
endothelial cells indicated that integrin b3 was significantly
upregulated in all our KSHV-infected samples (data not shown).
To confirm this we utilized quantitative real-time RT-PCR to
measure integrin b3 mRNA levels during KSHV latent infection
of endothelial cells. TIME or primary human dermal microvas-
cular endothelial cells were mock- or KSHV-infected and allowed
to establish latent infection for 48 hours. RNA from these cells was
extracted and subjected to real-time RT-PCR using primers
specific to integrin b3. Figure 1A shows that KSHV-infected
TIME cells had a 4.6-fold increase in integrin b3 expression as
compared to their mock counterparts. In primary endothelial cells
(ECs), KSHV induced a 3.5-fold increase in integrin b3 expression
over mock infection. In the cultures analyzed, greater than 90% of
the infected cells expressed LANA and less than 1% of the cells
expressed ORF 59, a marker of lytic infection, indicating that the
increase is likely to be a result of latent infection.
We next examined the expression of integrin b3 at the protein
level, using western blot analysis and flow cytometry. In TIME
cells latently infected with KSHV, total cellular integrin b3 was
significantly increased as visualized by Western blot analysis with
an antibody specific to integrin b3 (Figure 1B). In endothelial cells
aV is the only integrin a subunit that dimerizes with the b3
subunit. Flow cytometric analysis showed a specific increase in cell
surface expression of aVb3 during latent KSHV infection of
TIME cells (Figure 1C). The mean fluorescence intensity of mock-
infected cells was approximately 22.3, while KSHV infection
increased the mean to 31.9. Although there is only a modest
increase in cell surface aVb3 protein expression as compared to
total cellular expression, this shift was highly reproducible upon
multiple infections with different stocks of virus. Importantly,
expression of aVb3 increased in the majority of cells, indicating
that the increased surface protein expression was a property of
latently infected cells, not only the low percentage of lytically
infected cells.
Author Summary
Kaposi’s Sarcoma (KS) is the most common tumor of AIDS
patients world-wide and is characterized by very high
vascularization. The main KS tumor cell type is the spindle
cell, a cell of endothelial origin. Kaposi’s Sarcoma-
associated herpesvirus (KSHV), the etiologic agent of KS,
is found predominantly in the latent state in spindle cells.
In this study we examined how KSHV alters endothelial
cells to induce phenotypes common to angiogenesis and
tumor formation. Integrins are cell surface adhesion and
signaling proteins that can be involved in tumor growth
and tumor angiogenesis. We found that KSHV infection of
endothelial cells leads to increased expression of integrin
b3, a molecule that, when paired with its cognate a
subunit, aV, has been shown to be critical for tumor-
associated angiogenesis. KSHV infection promotes angio-
genic phenotypes in endothelial cells including adhesion,
motility and capillary morphogenesis, and these pheno-
types require expression and signaling through integrin
b3. Therefore, KSHV induction of integrin beta3 and
downstream signaling is required for the induction of
phenotypes thought to be critical for KS tumor formation.
aVb3 inhibitors are in clinical trials for inhibition of tumors
and we propose that these inhibitors may be clinically
relevant for treatment of KS tumors.
KSHV Induces Integrin b3 to Activate Angiogenesis
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Activation of integrins leads to recruitment of the intracellular
protein focal adhesion kinase (FAK) and autophosphorylation of
FAK on tyrosine 397 [47]. This autophosphorylation provides a
binding site for src family kinases, which subsequently become
activated. To determine if KSHV promotes integrin signaling
through FAK and Src, we analyzed the phosphorylation state of
these proteins at 48 hours post infection, after the establishment of
latency. Figure 2A shows an increase in FAK phosphorylation on
tyrosine 397 in KSHV-infected cells, compared to mock-infected
cells. Furthermore, Src is also phosphorylated more heavily on
tyrosine 416 in KSHV-infected cells. These experiments were also
performed in primary HMVECs, which upon infection undergo a
small but reproducible increase in Fak and Src activation
(Figure 2B). These data suggest that KSHV latent infection
promotes signaling through FAK and Src.
KSHV promotes focal adhesion complex turnover
A key process during cell migration is the regulation of focal
adhesion complexes, groups of signaling molecules that mediate
integrin signaling to the actin cytoskeleton. In order to better
understand the effect of KSHV induction of integrin b3o n
endothelial cell morphology, we examined the formation of focal
adhesion complexes in mock- or KSHV-infected cells. Figure 3A
shows the localization of the focal adhesion component vinculin in
mock-infected cells, which have many centrally localized focal
adhesions. The cells were also stained with phalloidin to identify
polymerized actin which is present throughout the cells. In
contrast, at 48 hours post-infection, endothelial cells latently
infected with KSHV have fewer focal adhesions but they are
strongly localized to the periphery, suggesting changes in the
formation and turnover of the focal adhesions (Figure 3C). The
polymerized actin also localizes to the periphery of the cell during
latent infection. The fewer focal adhesions and their localization at
the periphery suggest higher turnover and increased migration in
KSHV-infected cells.
To eliminate the potential effects of virus binding and entry,
UV-inactivated virus was used to infect cells. UV-irradiated virus
can bind and enter cells but there is no viral gene expression, as
determined by immunofluorescence with anti-LANA antibodies.
UV-inactivated virus did not alter the localization of focal
adhesions at 48 hours post-infection (Figure 3B). Interestingly, in
a mixed population of infected and uninfected cells, only infected
cells (as determined by staining with LANA-1 antibody) had
Figure 1. KSHV latent infection increases integrin b3 expression. A) TIME cells or primary human dermal microvascular cells were either
mock- or KSHV-infected, and allowed to establish latency for 48 hours. Relative abundances of integrin b3 mRNA were analyzed by one-step real-time
RT-PCR. B) 48 hours post-infection mock- or KSHV-infected TIME cells were harvested and cell lysates were separated by SDS-PAGE and stained with
an antibody to integrin b3. C) Mock- (red line) or KSHV-infected (blue line) TIME cells were stained with antibody to mouse IGG or aVb3 and analyzed
by flow cytometry.
doi:10.1371/journal.ppat.1002424.g001
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same population had more centrally localized focal adhesions,
similar to mock-infected cells (data not shown).
The cells were similarly stained with phalloidin and antibodies
to integrin b3. Integrins are known components of focal adhesion
complexes and have previously been shown to localize with
vinculin in these complexes [47,48,57]. As expected, integrin b3
had a very similar pattern of relocalization to the periphery as was
seen with antibodies to vinculin (Figure 3D–F). These data suggest
that latent KSHV infection promotes formation and turnover of
focal adhesions and that integrin aVb3 is activated and localized
to the newly formed focal adhesions. These observations are visible
throughout the culture, as can be seen in Figure 3G–I, where
multiple cells are shown stained for the latent antigen LANA (red)
and the actin cytoskeleton (green). Latently infected cells (Figure 3I,
arrows) show peripheral organization of actin filaments, compared
to the neighboring uninfected cells in the same culture (Figure 3I,
arrow heads), which have actin organization similar to mock-
infected or UV-inactivated virus (Figure 3G–H). Furthermore,
peripheral focal adhesions can be detected in greater than 90% of
the highly infected cells. In contrast, ORF59 is detected in less
than 1% of the cells (data not shown). In our endothelial infections
the KSHV late lytic protein K8.1, is detected in an even lower
percentage of the cells than ORF59 and we could only detect gB in
a very low percentage of cells as well (data not shown).
Importantly, gB has previously been shown to be detected only
in the low percentage of cells undergoing lytic replication [58].
Together, these data indicate that the vast majority of cells with
peripheral focal adhesions are latently infected and, while lytic
replication could play some paracrine role, it is unlikely to play a
primary role in organization of focal adhesion complexes during
KSHV infection as uninfected cells would be altered as well in this
scenario.
KSHV promotes endothelial cell adhesion and migration
in an RGD- and integrin b3-dependent fashion
We next wanted to determine whether KSHV latent infection
promotes an angiogenic phenotype in endothelial cells through the
activation of aVb3. Adhesion and migration of endothelial cells
are both critical for angiogenesis. Figure 4 shows the adhesion of
mock- or KSHV-infected cells to various concentrations of the
extracellular matrix proteins fibronectin and vitronectin, both of
which contain the arginine-glycine-aspartic acid (RGD) motif that
is recognized by a subset of integrins, including aVb3. Latent
Figure 2. FAK and Src are activated during KSHV latency in endothelial cells. TIME cells (A) or primary dHMVECs (B) were mock- or KSHV-
infected. At 48 hpi, cell extracts were analyzed by immunoblot analysis with the indicated phospho-specific or total-protein antibodies. Blots were
stripped and probed with an antibody to b-actin as a loading control. The numbers below the lanes indicate the relative abundance of each major
band. These experiments were repeated three times with similar results.
doi:10.1371/journal.ppat.1002424.g002
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both fibronectin (Figure 4A) and vitronectin (Figure 4B) compared
to mock-infected cells. None of the cells adhered to either collagen
I, which lacks an RGD motif, or laminin, suggesting the increased
adhesion is specific to fibronectin and vitronectin (data not shown).
Short RGD-containing peptides will compete with vitronectin and
fibronectin binding to RGD-dependent integrins, like aVb3, and
inhibit integrin-dependent adherence to these substrates. Interest-
ingly, an RGD-containing short peptide, but not a control RAD-
or RGE-containing peptide, inhibited KSHV-induced adhesion to
fibronectin or vitronectin. The same peptides had little effect on
mock-infected cells (Figure 4C–D). This indicates that KSHV-
infected cells require RGD-binding integrins for increased
adherence while mock-infected cells are relatively unaffected by
the concentrations of RGD peptides used.
In addition to adhesion, integrin activation can promote
migration of endothelial cells through formation and turnover of
focal adhesions. In Figure 3 we demonstrated a strong reorgani-
zation of focal adhesions during KSHV latency in endothelial
cells. We therefore examined the effect of KSHV infection on
endothelial cell migration. 48 hours post-infection, endothelial
cells were seeded on a transwell membrane with 8 mm pore size
and allowed to migrate for 1.5 hours. Approximately three times
more KSHV-infected endothelial cells migrated through the pores
Figure 3. KSHV latent infection promotes turnover of focal adhesions and relocalization of integrin b3. Primary HMVECs were infected
with mock (A,D,G), UV-inactivated KSHV (B,E,H), or KSHV (C,F,I) and allowed to establish latency for 48 hours. A–C) Cells were then fixed and stained
for vinculin (red) and phalloidin to visualize polymerized actin (green). Cells were mounted in medium containing DAPI (blue). Arrows indicate focal
adhesions. Images were taken at 630x magnification. D–F) Cells were stained with antibody to integrin b3 (red) and phalloidin (green). Arrows
indicate integrin b3 localized to focal adhesions. Images were taken at 630x magnification. G–I) Cells were stained with antibody to LANA (red) and
phallodin (green) as above. Images were taken at 400x magnification. I) Arrows show LANA-positive KSHV-infected cells, while arrow heads point to
LANA-negative uninfected cells in the same culture.
doi:10.1371/journal.ppat.1002424.g003
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migration was not due to increased proliferation, since KSHV
infection does not promote proliferation in TIME cells as
determined by uptake of BrdU (data not shown). To determine
whether this enhanced migration was due to increased integrin
signaling, we used a Src kinase inhibitor to block downstream
integrin signaling. The Src kinase inhibitor led to a decrease in the
mean number of mock- and KSHV-infected cells that migrated
through the pores (Figure 5D). However, the lower dose of the Src
kinase inhibitor decreased the migration of mock-infected cells by
approximately 50% while migration of KSHV-infected cells was
reduced more than 80% (Figure 5E). Therefore, KSHV-infected
cell migration is sensitive to Src inhibitors to a greater degree than
migration of mock-infected cells.
Integrin b3 activation is required for KSHV-induced
capillary morphogenesis
KSHV latent infection leads to small increases in the ability of
endothelial cells to organize into capillary-like structures in three-
dimensional culture at 6 hours after seeding. However, these
effects are not consistently statistically significant (our unpublished
observations and Figure 6A). Due to the increased integrin activity
and signaling, we hypothesized that KSHV infection may promote
capillary morphogenesis through a different pathway than
uninfected cells. Therefore, we examined the role of integrin b3
in the ability of KSHV-infected cells to organize in three-
dimensional culture on Matrigel. We first tested whether RGD-
binding integrins were involved by using an RGD-containing
peptide to block integrin activity. Interestingly, in the presence of
the RGD-containing peptide, KSHV-infected cells formed
approximately 85% fewer capillary-like structures while mock-
infected cells lost only 40% of their activity (Figure 6A and B). This
indicates that KSHV-infected cells are more sensitive to inhibition
of integrin activation as compared to mock-infected cells and
suggests that KSHV-infected cells become reliant on integrin
activity for this angiogenic phenotype.
In order to determine if this effect was due specifically to
integrin b3 we used siRNA to knock down integrin b3 protein
expression. Cells were transfected with siRNA 24 hours post-
infection with KSHV and harvested for analysis 48 hours later (at
72 hours post-infection). Figure 6 (C and D) shows that the
expression of aVb3 integrin complexes is significantly reduced
upon transfection of integrin b3 siRNA. Interestingly, aVb3
expression is reduced more strongly in mock-infected cells
(Figure 6C) than in KSHV-infected cells (Figure 6D). Mock-
infected cells with control siRNA have a geometric mean
fluorescence of 22.3, which drops to 3.4 in cells expressing
integrin b3 siRNA, a greater than 6.5 fold decrease in expression.
In contrast, in KSHV-infected cells, the geometric mean
fluorescence of integrin b3 goes from 31.9 in control siRNA-
expressing cells to 6.9 in b3 siRNA-expressing cells, which is still
above background fluorescence levels and is a 4.6 fold decrease.
Figure 4. KSHV latent infection promotes adhesion to fibronectin and vitronectin in an integrin-dependent fashion. TIME cells were
mock- or KSHV-infected and 48 hours post-infection cells were plated onto 96-well plates coated with fibronectin (A) or vitronectin (B). Cells were
allowed to adhere for 90 minutes after which non-adherent cells were washed off. The number of adherent cells was determined by alkaline
phosphatase activity. Mock-infected cell adhesion is indicated with squares and KSHV-infected cell adhesion is indicated with triangles. C and D)
48 hours post-infection, mock- (squares) and KSHV- (triangles) infected cells were pretreated with RGD-containing (red lines) or control peptide (RAD
for (C) and RGE for (D), black lines) for 15 minutes on ice before assaying for adhesion to fibronectin (C) or vitronectin (D).
doi:10.1371/journal.ppat.1002424.g004
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KSHV-infected cells. Integrin b3 specific siRNA impaired KSHV-
induced capillary morphogenesis (Figure 6E and F, p-val-
ue=0.003) but had little effect on mock-infected cells (a 33%
versus 12% decrease in capillary formation respectively), despite
the small amount of residual integrin b3 expression in KSHV-
infected cells with the b3 specific siRNA. This suggests that the
KSHV-induced angiogenic phenotype specifically requires inte-
grin b3 expression.
To further confirm that integrin activation and signaling during
KSHV latent infection is required for the KSHV-induced
angiogenic phenotype, we next determined whether Src kinase
activity is required for KSHV-induced capillary morphogenesis.
Mock- and KSHV-infected cells were treated with the indicated
concentrations of Src kinase inhibitor SKI-1 or DMSO alone and
plated on Matrigel matrix. Similar to the effects of inhibition by
the RGD-containing peptide or integrin b3 siRNA, inhibition of
Src kinase had a greater impact on KSHV-infected cells than on
Figure 5. KSHV latent infection promotes endothelial cell transwell migration in a Src-dependent fashion. Cells were infected with
mock or KSHV and, 48 hours post-infection, were plated on fibronectin-coated transwells. Cells were allowed to migrate through the pores at 37uC
for 1.5 hours and subsequently fixed and stained with crystal violet. The cells on the upper side of the membrane were removed with a cotton swab,
the membranes were mounted on slides and the cells that migrated were photographed. A and B) Representative images of migrated mock- (A) and
KSHV-infected (B) cells. C) Quantification of a representative experiment showing the number of migrated cells per field for 10 fields counted per
transwell. Asterisk indicates a p-value of less than 0.05 compared to mock-infected cells. D–E) Cells (48 hpi) were treated with the Src kinase inhibitor
SKI-1 at the time of plating on fibronectin-coated transwells and are presented as number of cells per field (D) and percent inhibition by SKI-1 (E).
Double asterisks indicate a p-value of less than 0.005 compared to DMSO control.
doi:10.1371/journal.ppat.1002424.g005
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treated with 5 nM SKI-1 had an approximate 5-fold decrease in
the number of capillaries formed compared to DMSO-treated
cells. In contrast, mock-infected cells retained nearly complete
ability to organize on Matrigel. At higher concentrations of SKI-1,
capillary formation of KSHV-infected endothelial cells was
completely eliminated while mock-infected cells had only modest
decreases in capillary formation. To further demonstrate that the
effects seen were due to inhibition of Src, another Src kinase
inhibitor, su6656, was used. Su6656 had a similar effect on
KSHV-infected cells as SKI-1 (Figure 6G and H). Similar
experiments with primary HMVECS yielded comparable results
(data not shown). Thus, three different methods of inhibiting
integrin signaling – RGD peptides, siRNA to integrin b3, and
chemical inhibition of downstream integrin signaling – blocked
capillary formation by KSHV infected endothelial cells in a three
dimensional matrix more significantly than in mock infected cells.
Discussion
During angiogenesis, activated endothelial cells disrupt the
extracellular matrix, proliferate and migrate towards angiogenic
stimuli, gain traction into new areas through increased adhesion to
specific substrates, and organize into preliminary vasculature.
These activities are necessary for vascularization of solid tumors
and contribute to the promotion of tumor formation and
metastasis. As has been described by others, KSHV is likely to
promote angiogenesis in a paracrine fashion to promote new blood
vessel growth in the KS tumor [10,12,19–21,28,41,59]. Here we
found that KSHV also directly induces angiogenic phenotypes in
Figure 6. Capillary morphogenesis of KSHV-infected cells requires aVb3 integrin. A)TIME cells were mock- or KSHV-infected and, 48 hpi,
plated on Matrigel in the presence of either RAD- or RGD-containing peptide in complete medium. B) The data in the graphs are the mean number of
capillaries per field (left) and the percent of RAD peptide controls (right). C–D) TIME cells were mock- (C) or KSHV-infected (D), and, at 24 hpi,
transfected with either control siRNA or siRNA specific to integrin b3. Cells were stained with antibody to mouse IGG (red line) or aVb3 integrin (blue
line: control siRNA; green line: integrin b3 siRNA) and analyzed by flow cytometry. E) At 72 hours post infection and 48 hours post transfection of
integrin b3 siRNA, mock- and KSHV-infected cells were plated on Matrigel in complete media and cultured for 6 hours. F) Quantitation of three
separate experiments similar to the one shown in E. G) TIME cells were mock- or KSHV-infected and, 48 hpi, plated on Matrigel in the presence of
either DMSO, SKI-1, or su6656. H) Quantification of three separate experiments similar to that shown in G. Asterisks indicate a p-value of less than 0.05
compared to DMSO or negative control. Double asterisks indicate a p-value of less than 0.005 compared to DMSO control.
doi:10.1371/journal.ppat.1002424.g006
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increased cell motility and cell adhesion. Therefore, angiogenic
phenotypes induced in latently infected endothelial cells may
promote angiogenesis in KS tumors but may also directly be
involved in the activation of the endothelial tumor cells themselves.
Integrins are involved in many processes of both angiogenesis
and oncogenesis. Integrins have been shown to be critical for
angiogenic phenotypes such as adhesion, migration, and anchor-
age-independent survival (reviewed in [47,48]). Integrins have also
been shown to be important in oncogenesis of many cell types
(reviewed in [60]). In particular, integrin aVb3 is expressed on
blood vessels in human tumor biopsy samples, but not on vessels in
normal human tissues, suggesting a role in tumor-associated
angiogenesis [50,51]. Furthermore, inhibition of integrins, and in
particular aVb3, can inhibit angiogenesis and promote regression
of tumors by inducing apoptosis of endothelial cells [52–55]. We
found that KSHV not only induces the expression of integrin b3
leading to increased surface expression of aVb3, but latent
infection also leads to the activation of aVb3 and downstream
activation of FAK and Src. Importantly, integrin signaling,
specifically aVb3, is necessary for KSHV induction of angiogenic
phenotypes including cell motility and adhesion.
Regulation of angiogenesis is a complex process that involves
cross talk between multiple signaling pathways. Integrin signaling
complexes have been shown to interact with angiogenic growth
factor receptors, such as VEGF and basic fibroblast growth factor
[48]. Specifically, interaction between aVb3 and VEGF receptor 2
can lead to phosphorylation of the cytoplasmic tail of b3 as well as
increased phosphorylation of VEGF receptor 2 in a Src-dependent
fashion [61]. Interestingly, b3 knockout mice exhibit increased
pathological angiogenesis, due to increased expression and
signaling through VEGF receptor 2 [62,63]. However, knock-in
expression of a mutant b3 that lacks phosphorylation sites blocks
VEGF-induced pathological angiogenesis in these mice [64].
Integrin aVb3 also plays a role in regulating the expression of
VEGF; its activation can increase VEGF secretion by tumor cells
[65]. Thus, upregulation of VEGF and its receptors by KSHV
likely acts in concert with increased aVb3 signaling to promote
angiogenesis.
Interestingly, KSHV-infected cells become dependent upon
aVb3 for capillary formation. Inhibition of integrin signaling and
aVb3 had small effects on the ability of uninfected endothelial cells
to form capillary-like structures on Matrigel. However, during
KSHV latency, capillary formation is extremely sensitive to
inhibitors of aVb3 and integrin signaling. In uninfected cells aVb3
is localized with focal adhesions all over the cell, while in infected
cells aVb3 is localized to the focal adhesions at the periphery. It is
possible that the dramatic change in focal adhesions and
polymerized actin in the infected cells leads to increased reliance
on aVb3. However, whether the increased sensitivity is due to a
switch in the infected cell solely to integrin signaling for capillary
formation or if there is a decrease in a compensatory pathway is
unknown. In either event, this provides a good target for therapy,
as the latently infected cells are more sensitive than mock-infected
cells to inhibitors of integrin signaling.
Integrins are also used for KSHV binding and entry into cells. It
was first demonstrated that a3b1 was a receptor for KSHV on
endothelial cells [66]. Subsequently it was shown that gB binds to
aVb3 and that aVb3 may be the dominant integrin for binding
and entry [56]. Interestingly, both of these integrins together with
CD98 may form an entry complex [67]. During binding and
entry, gB binding to integrins leads to activation of the integrins
and subsequent activation of FAK and focal adhesions [68–70].
While this phenomenon is similar to what we describe, we found
that activation of FAK and Src also occurs during latency and, at
the time points we examined, this is not due to initial binding and
entry of the virus. Additionally, gB has previously been shown to
only be expressed in cells undergoing lytic replication and cannot
be detected at the late times post-infection that we examined [58].
While cells undergoing lytic replication are present in our cultures,
less than 1% of the cells express ORF 59, a common marker of
lytic infection. Using an immunofluorescence assay we find that
most of the infected cells have altered focal adhesions at the
periphery. Furthermore, the bulk of the cells shift expression of
aVb3 and the bulk of the population is more motile and more
adherent, indicating that the phenomenon we are examining is
occurring in latently infected cells. Importantly, in cultures where
we have a mixed population of uninfected and KSHV-infected
cells, only the cells that have LANA expression, i.e. are latently
infected, have relocalized actin to the periphery (Figure 3I) and
have focal adhesions at the periphery as well (not shown). Taken
together, these data all indicate that there is a factor in the latent
cells that is necessary for activation of integrin signaling and
induction of the angiogenic phenotypes. While paracrine factors
from the low percentage of lytically infected cells could play some
role in the angiogenic phenotypes described, a latent factor is still
required. The viral gene or genes upregulating integrin b3 and
activating aVb3 and FAK are currently unknown and will be the
focus of future studies.
Inhibition of integrins and integrin signaling has been proposed
as a target for tumor therapy through inhibition of tumor cell
growth itself and through inhibition of neo-angiogenesis. A
number of inhibitors of integrin signaling are in clinical trials for
tumors that have increased levels of integrins and specifically
aVb3 (reviewed in [49,60]). Importantly, an inhibitor of aVb3i s
in phase3 trials for inhibition of tumor formation. Based on the
studies presented here, we believe that aVb3 may be a good target
for therapy to treat KS tumors. It is difficult to target herpesvirus
latency due to the limited viral gene expression. However, through
a better understanding of the host cell requirements for latency
new therapeutic targets can be identified. Integrin b3 induction
and activation by KSHV during latency is critical for a number of
phenotypes important for tumor growth and latency, making it an
attractive target for therapy.
Materials and Methods
Cells
Primary human dermal microvascular endothelial cells
(hDMVEC) and TIME cells [71] were maintained as monolayer
cultures in EBM-2 medium (Lonza) supplemented with 5% fetal
bovine serum, vascular endothelial growth factor, basic fibroblast
growth factor, insulin-like growth factor 3, epidermal growth
factor, and hydrocortisone (EGM-2 media). BCBL-1 [72] and
BJAB cells [73] were maintained in RPMI 1640 medium (Celgro;
Mediatech, Inc.) supplemented with 10% fetal bovine serum,
penicillin, streptomycin, glutamine, and b-mercaptoethanol.
Viruses and infection
KSHV inoculum was obtained from BCBL-1 cells (5610
5 cells/
ml) induced with 20 ng of TPA (12-O-tetradecanoylphorbol-13-
acetate; Sigma)/ml. After 5 days, cells were pelleted, and the
supernatant was run through a 0.45-mm-pore-size filter (What-
man). Virions were pelleted at 30,000xg for 2 h in a JA-14 rotor,
Avanti-J-25 centrifuge (Beckman Coulter). The viral pellet was
resuspended in EGM-2 without supplements. KSHV infections of
TIME and primary hDMVEC were performed in serum-free
EBM-2 supplemented with 8 ug/ml polybrene for 3 h, after which
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were performed identically except that concentrated virus was
omitted from the inoculum. For all experiments, infection rates
were assessed by immunofluorescence using antibodies against the
latency-associated nuclear antigen (LANA) and the lytic protein
ORF59. In all infections performed with wild-type (wt) KSHV
.85% of the cells were LANA-positive and ,1% were ORF59-
positive. UV inactivation of KSHV viral stocks (561,200 mJ) was
performed in a UV Stratalinker 1800 (Stratagene).
RNA isolation and quantitative RT-PCR
Total RNA was isolated from TIME cells using the RNeasy Plus
Minikit (Qiagen). One hundred or 500 ng of total RNA was used
in a SuperScript III, Platinum SYBR green, one-step, quantitative
reverse transcription PCR (RT-PCR; Invitrogen) according to
manufacturer’s protocols with the primers for either GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) (forward, 59-AAG
GTG AAG GTC GGA GTC AAC G-39; reverse, 59-TGG AAG
ATG GTG ATG GGA TTT C-39) or integrin b3 (forward, 59-
GCA AGG ATG CAG TGA ATT GT-39; reverse, 59-CTT GGG
ACA CTC TGG CTC TT-39). Relative abundances of integrin
b3 mRNA were normalized by the delta threshold cycle method to
the abundance of GAPDH, with mock-infected TIME cells set to
1. Error bars reflect standard errors of the means (four
experiments).
Immunoblot analysis
Cells were harvested with a cell scraper and pelleted using the
Sorvall RT7 Plus centrifuge at 4uC. An aliquot of the cells was
seeded onto chamber slides for immunofluorescence analysis. Cell
pellets were washed once in cold phosphate-buffered saline and
then resuspended in lysis buffer (20 mM Tris [pH 7.0], 2 mM
EGTA, 5 mM EDTA, phosphatase inhibitors, protease inhibitors,
and 1% Triton X-100). Samples were sonicated, rocked at 4uC for
30 minutes, and then spun at 6,000 x g at 4uC. Cell extracts were
fractionated on a sodium dodecyl sulfate-polyacrylamide gel
electrophoresis gel, and the proteins were transferred electropho-
retically to Immobilon P polyvinylidene difluoride membranes
(Millipore) in Tris-glycine buffer (25 mM Tris, 192 mM glycine,
20% methanol). Blots were incubated with the indicated antibody
(dilutions: 1:1000 for anti-integrin b3, 1:1000 for anti-phospho-
FAK and anti-phosphoSrc; 1:20,000 for anti-actin) and subse-
quently with horseradish peroxidase-conjugated goat anti-mouse
or rabbit immunoglobulin G (1:10,000; IgG; Jackson ImmunoR-
esearch). Immunoreactive proteins were visualized by chemilumi-
nescence using the Amersham ECL Plus Western blotting
detection reagents (GE Healthcare). Differences in band intensity
were quantified by densitometric methods.
Immunofluorescence
Mock- or KSHV-infected TIME cells were seeded on LabTek
Permanox four-well chamber slides (Fisher Scientific) and fixed
with 4% (wt/vol) paraformaldehyde in phosphate-buffered saline.
Immunofluorescence was performed as described previously [4].
Briefly, cells were incubated in Tris-Buffered Saline (20 mM Tris,
150 mM NaCl, pH 7.6; TBS) containing 1% normal goat serum
followed by incubation with primary antisera at a dilution of 1:100
(anti-integrin b3; anti-vinculin) or 1:1,000 (rabbit or rat anti-
LANA; mouse anti-ORF59) diluted in TBS containing 1% BSA
overnight. Cells were then incubated with fluor-conjugated
secondary antibodies (goat anti-rabbit Alexa Fluor 488, goat
anti-mouse Alexa Fluor 594, or goat anti-rat Alexa Fluor 488;
Molecular Probes/Invitrogen; Fluorescein-conjugated phalloidin;
Sigma) for 2 hours. Cells were mounted in medium containing
DAPI (49,69-diamidino-2-phenylindole) before being viewed under
a Zeiss LSM 510 Meta confocal microscope. Images were
analyzed using the Zeiss Zen 2009 LE imaging software.
Transfection of siRNA
siRNA specific to integrin b3 and negative-control oligonucle-
otides were designed and synthesized by Ambion (Austin, TX).
The following oligonucleotide sequences were used: integrin b3
(Ambion identification [ID] no. 112581; sense, 59-GCU AAU
UCU UUG ACC UGU UdTdT-39) and negative-control siRNA
(sense, 59-AGU ACU GCU UAC GAU ACG GdTdT-39). At
24 h post-infection, mock- or KSHV-infected TIME cells were
transfected with 3 mg siRNA using Amaxa’s Nucleofector kit
(Cologne, Germany) according to the manufacturer’s protocol.
The transfection efficiency for siRNA was approximately 90%
when it was assessed with 6-carboxyfluorescein-labeled negative-
control siRNA. Transfected cells were harvested for analysis after
an additional 2 days of incubation at 37uC.
Flow cytometric analysis
Monolayers of cells grown in 60-mm tissue culture dishes were
washed once with phosphate-buffered saline (PBS) containing
0.04% EDTA and incubated with 2 ml of cell dissociation solution
(Sigma, St. Louis, MO) to remove cells from plates. Cells were
washed once with DMEM containing 10% FBS and fixed in 4%
paraformaldehyde in TBS for 10 minutes on ice. Cells were then
pelleted and resuspended in 0.5 ml TBS with 1% goat serum for
20 min on ice. Cells were pelleted and incubated with mouse anti-
aVb3( 2 mg/ml; LM609; Millipore) or mouse IGG control
prepared in 0.5 ml of TBS with 1% BSA for 30 min on ice.
Following incubation, cells were washed twice with TBS/1% BSA
and then incubated with anti-mouse secondary antibody conju-
gated to Alexafluor 488 (Invitrogen; diluted 1:200 in 0.5 ml of
TBS containing 1% BSA) for 30 min on ice. The stained cells were
washed twice with TBS containing 1% BSA, resuspended in
0.5 ml of TBS containing 1% BSA, and analyzed by FACScan
caliber flow cytometer (Becton-Dickinson, Franklin Lakes, NJ).
Data was analyzed using FloJo flow cytometry analysis software
(Tree Star, Inc.; Ashland, OR).
Cell adhesion assays
Cell adhesion assays were performed using Nunc 96-well
Maxisorp plates as described previously [74]. Briefly, wells were
coated with different concentrations of collagen, fibronectin,
laminin, or vitronectin in TBS containing 2 mM each of CaCl2
and MgCl2 overnight at 4uC. The next day, plates were washed
with TBS and blocked with 200 ml of TBS Ca/Mg containing 1%
BSA for 1 hour at room temperature. Cells were resuspended in
20 mM HEPES, 150 mM NaCl, 4 mg/ml BSA (pH 7.4) and
plated at 5610
4 cells/well. Cells were allowed to adhere at 37uCi n
a humidified incubator for 1.5 hours. Nonadherent cells were
gently washed off with TBS containing Ca/Mg, and the number
of adherent cells was determined by measuring the standard
intracellular acid phosphatase activity. For inhibition studies on
fibronectin, cells were treated with GRADSPK or GRGDSPK
peptides (Sigma) in HEPES buffer for 15 minutes on ice prior to
plating. For inhibition studies on vitronectin, cells were treated
with GRGES or GRGDS peptides (Peptides International) in
HEPES buffer for 15 minutes on ice prior to plating.
Transwell migration
For transwell assays, transwell filters (Costar 3422) were placed
in a 24-well dish and coated on the bottom side with 0.5 ml of
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The filter was rinsed with PBS and then blocked with 0.5 ml of 2%
bovine serum albumin (BSA) prepared in PBS for 1 h at room
temperature. Following blocking, the filter was rinsed with PBS,
0.5 ml of serum-free DMEM medium was added to the bottom of
each well. Cells were resuspended at 1610
5 cells/ml in serum free
medium and 0.1 ml was added to the top of each well. Each
condition was done in duplicate. Following 1.5 hours in a 37uC
tissue culture incubator, the cells and medium were aspirated and
the upper side of the membrane wiped with a cotton swab. The
cells that had migrated through the membrane and attached to the
bottom of the filter were fixed with 4% paraformaldehyde and
stained with crystal violet. The mean number of cells migrated
through the filter was determined by counting ten high power
fields (6100). For inhibition studies, cells were incubated with
SKI-1 (Calbiochem) for 15 minutes on ice prior to addition to the
transwell.
Three-dimensional culture of endothelial cells
Matrigel (10 mg/ml; BD Biosciences, Bedford, MA) was applied
at 0.5 ml/35 mm in a tissue culture dish and incubated at 37uC
for at least 30 min to harden. Mock- or KSHV-infected cells were
removed using trypsin-EDTA, washed with growth medium once,
and resuspended at 1.5610
5 cells per ml in growth medium. Cells
(1 ml) were gently added to the Matrigel-coated plates, incubated
at 37uC, monitored for 6 h, and photographed in digital format
using a Nikon microscope. Capillaries were defined as cellular
processes connecting two bodies of cells. Ten fields of cells were
counted for each condition and the mean and standard deviations
were determined. For inhibition studies, GRADSPK or
GRGDSPK peptides, SKI-1 (Calbiochem), or su6656 (Sigma)
were added at the time of plating on Matrigel.
Statistics
Statistical differences between groups were evaluated with
Student’s t-test (two-tailed). Mean6SD was shown and a p-value of
#0.05 was considered significant and indicated by asterisk.
Acknowledgments
The authors would like to thank Sreetha Sidharthan for technical
assistance.
Author Contributions
Conceived and designed the experiments: TAD ML. Performed the
experiments: TAD KDG. Analyzed the data: TAD ML. Wrote the paper:
TAD ML.
References
1. Wabinga H, Parkin D, Wabwire-Mangen F, Mugerwa J (1993) Cancer in
Kampala, Uganda, in 1989-91: changes in incidence in the era of AIDS.
Int J Cancer 54: 26–36.
2. Chokunonga E, Levy L, Bassett M, Mauchaza B, Thomas D, et al. (2000)
Cancer incidence in the African population of Harare, Zimbabwe: second results
from the cancer registry 1993-1995. Int J Cancer 85: 54–59.
3. Staskus K, Zhong W, Gebhard K, Herndier B, Wang H, et al. (1997) Kaposi’s
sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor
cells. J Virol 71: 715–719.
4. Lagunoff M, Bechtel J, Venetsanakos E, Roy A, Abbey N, et al. (2002) De novo
infection and serial transmission of Kaposi’s sarcoma-associated herpesvirus in
cultured endothelial cells. J Virol 76: 2440–2448.
5. Bechtel JT, Liang Y, Hvidding J, Ganem D (2003) Host range of Kaposi’s
sarcoma-associated herpesvirus in cultured cells. J Virol 77: 6474–6481.
6. Lagunoff M, Lukac DM, Ganem D (2001) Immunoreceptor tyrosine-based
activation motif-dependent signaling by Kaposi’s sarcoma-associated herpesvirus
K1 protein: effects on lytic viral replication. J Virol 75: 5891–5898.
7. Wang L, Damania B (2008) Kaposi’s sarcoma-associated herpesvirus confers a
survival advantage to endothelial cells. Cancer Res 68: 4640–4648.
8. Couty J, Lupu-Meiri M, Oron Y, Gershengorn M (2009) Kaposi’s sarcoma-
associated herpesvirus-G protein-coupled receptor-expressing endothelial cells
exhibit reduced migration and stimulated chemotaxis by chemokine inverse
agonists. J Pharmacol Exp Ther 329: 1142–1147.
9. Qian L, Xie J, Ye F, Gao S (2007) Kaposi’s sarcoma-associated herpesvirus
infection promotes invasion of primary human umbilical vein endothelial cells by
inducing matrix metalloproteinases. J Virol 81: 7001–7010.
10. Sadagopan S, Sharma-Walia N, Veettil M, Bottero V, Levine R, et al. (2009)
Kaposi’s sarcoma-associated herpesvirus upregulates angiogenin during infec-
tion of human dermal microvascular endothelial cells, which induces 45S rRNA
synthesis, antiapoptosis, cell proliferation, migration, and angiogenesis. J Virol
83: 3342–3364.
11. Sadagopan S, Sharma-Walia N, Veettil M, Raghu H, Sivakumar R, et al. (2007)
Kaposi’s sarcoma-associated herpesvirus induces sustained NF-kappaB activa-
tion during de novo infection of primary human dermal microvascular
endothelial cells that is essential for viral gene expression. J Virol 81: 3949–3968.
12. Sivakumar R, Sharma-Walia N, Raghu H, Veettil M, Sadagopan S, et al. (2008)
Kaposi’s sarcoma-associated herpesvirus induces sustained levels of vascular
endothelial growth factors A and C early during in vitro infection of human
microvascular dermal endothelial cells: biological implications. J Virol 82:
1759–1776.
13. Masood R, Cesarman E, Smith DL, Gill PS, Flore O (2002) Human
herpesvirus-8-transformed endothelial cells have functionally activated vascular
endothelial growth factor/vascular endothelial growth factor receptor.
Am J Pathol 160: 23–29.
14. Carroll P, Brazeau E, Lagunoff M (2004) Kaposi’s sarcoma-associated
herpesvirus infection of blood endothelial cells induces lymphatic differentiation.
Virology 328: 7–18.
15. Carroll P, Kenerson H, Yeung R, Lagunoff M (2006) Latent Kaposi’s sarcoma-
associated herpesvirus infection of endothelial cells activates hypoxia-induced
factors. J Virol 80: 10802–10812.
16. Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, et al. (2004)
Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the
lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 36:
687–693.
17. Hong YK, Foreman K, Shin JW, Hirakawa S, Curry CL, et al. (2004)
Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-
associated herpesvirus. Nat Genet 36: 683–685.
18. Sharma-Walia N, Paul AG, Bottero V, Sadagopan S, Veettil MV, et al. (2010)
Kaposi’s sarcoma associated herpes virus (KSHV) induced COX-2: a key factor
in latency, inflammation, angiogenesis, cell survival and invasion. PLoS Pathog
6: e1000777.
19. Vart R, Nikitenko L, Lagos D, Trotter M, Cannon M, et al. (2007) Kaposi’s
sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled
receptor regulate angiopoietin-2 expression in lymphatic endothelial cells.
Cancer Res 67: 4042–4051.
20. Ye F, Blackbourn D, Mengel M, Xie J, Qian L, et al. (2007) Kaposi’s sarcoma-
associated herpesvirus promotes angiogenesis by inducing angiopoietin-2
expression via AP-1 and Ets1. J Virol 81: 3980–3991.
21. Ma T, Jham BC, Hu J, Friedman ER, Basile JR, et al. (2010) Viral G protein-
coupled receptor up-regulates Angiopoietin-like 4 promoting angiogenesis and
vascular permeability in Kaposi’s sarcoma. Proc Natl Acad Sci U S A 107:
14363–14368.
22. Mansouri M, Rose P, Moses A, Fru ¨h K (2008) Remodeling of endothelial
adherens junctions by Kaposi’s sarcoma-associated herpesvirus. J Virol 82:
9615–9628.
23. Guilluy C, Zhang Z, Bhende PM, Sharek L, Wang L, et al. (2011) Latent KSHV
infection increases the vascular permeability of human endothelial cells. Blood
118: 5344–5354.
24. Qian L, Greene W, Ye F, Gao S (2008) Kaposi’s sarcoma-associated herpesvirus
disrupts adherens junctions and increases endothelial permeability by inducing
degradation of VE-cadherin. J Virol 82: 11902–11912.
25. Dwyer J, Le Guelte A, Galan Moya EM, Sumbal M, Carlotti A, et al. (2011)
Remodeling of VE-cadherin junctions by the human herpes virus 8 G-protein
coupled receptor. Oncogene 30: 190–200.
26. Qin Z, Dai L, Slomiany MG, Toole BP, Parsons C (2010) Direct activation of
emmprin and associated pathogenesis by an oncogenic herpesvirus. Cancer Res
70: 3884–3889.
27. Dai L, Bratoeva M, Toole BP, Qin Z, Parsons C (2011) KSHV activation of
VEGF secretion and invasion for endothelial cells is mediated through viral
upregulation of emmprin-induced signal transduction. Int J Cancer. E-pub
ahead of print;doi: 10.1002/ijc.26428.
28. Aoki Y, Jaffe E, Chang Y, Jones K, Teruya-Feldstein J, et al. (1999) Angiogenesis
and hematopoiesis induced by Kaposi’s sarcoma-associated herpesvirus-encoded
interleukin-6. Blood 93: 4034–4043.
KSHV Induces Integrin b3 to Activate Angiogenesis
PLoS Pathogens | www.plospathogens.org 11 December 2011 | Volume 7 | Issue 12 | e100242429. Bakken T, He M, Cannon ML (2010) The phosphatase Shp2 is required for
signaling by the Kaposi’s sarcoma-associated herpesvirus viral GPCR in primary
endothelial cells. Virology 397: 379–388.
30. Masood R, Xia G, Smith DL, Scalia P, Still JG, et al. (2005) Ephrin B2
expression in Kaposi sarcoma is induced by human herpesvirus type 8:
phenotype switch from venous to arterial endothelium. Blood 105: 1310–1318.
31. Xie J, Pan H, Yoo S, Gao S (2005) Kaposi’s sarcoma-associated herpesvirus
induction of AP-1 and interleukin 6 during primary infection mediated by
multiple mitogen-activated protein kinase pathways. J Virol 79: 15027–15037.
32. McAllister SC, Hansen SG, Ruhl RA, Raggo CM, DeFilippis VR, et al. (2004)
Kaposi sarcoma-associated herpesvirus (KSHV) induces heme oxygenase-1
expression and activity in KSHV-infected endothelial cells. Blood 103:
3465–3473.
33. Fonsato V, Buttiglieri S, Deregibus MC, Bussolati B, Caselli E, et al. (2008)
PAX2 expression by HHV-8-infected endothelial cells induced a proangiogenic
and proinvasive phenotype. Blood 111: 2806–2815.
34. Cai Q, Murakami M, Si H, Robertson E (2007) A potential alpha-helix motif in
the amino terminus of LANA encoded by Kaposi’s sarcoma-associated
herpesvirus is critical for nuclear accumulation of HIF-1alpha in normoxia.
J Virol 81: 10413–10423.
35. Shin Y, Joo C, Gack M, Lee H, Jung J (2008) Kaposi’s sarcoma-associated
herpesvirus viral IFN regulatory factor 3 stabilizes hypoxia-inducible factor-1
alpha to induce vascular endothelial growth factor expression. Cancer Res 68:
1751–1759.
36. Wang L, Dittmer D, Tomlinson C, Fakhari F, Damania B (2006) Immortal-
ization of primary endothelial cells by the K1 protein of Kaposi’s sarcoma-
associated herpesvirus. Cancer Res 66: 3658–3666.
37. Boshoff C, Endo Y, Collins P, Takeuchi Y, Reeves J, et al. (1997) Angiogenic
and HIV-inhibitory functions of KSHV-encoded chemokines. Science 278:
290–294.
38. Stine J, Wood C, Hill M, Epp A, Raport C, et al. (2000) KSHV-encoded CC
chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively
chemoattracts TH2 cells. Blood 95: 1151–1157.
39. Arvanitakis L, Geras-Raaka E, Varma A, Gershengorn M, Cesarman E (1997)
Human herpesvirus KSHV encodes a constitutively active G-protein-coupled
receptor linked to cell proliferation. Nature 385: 347–350.
40. Montaner S, Sodhi A, Pece S, Mesri E, Gutkind J (2001) The Kaposi’s sarcoma-
associated herpesvirus G protein-coupled receptor promotes endothelial cell
survival through the activation of Akt/protein kinase B. Cancer Res 61:
2641–2648.
41. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, et al. (2000) The Kaposi’s
sarcoma-associated herpes virus G protein-coupled receptor up-regulates
vascular endothelial growth factor expression and secretion through mitogen-
activated protein kinase and p38 pathways acting on hypoxia-inducible factor
1alpha. Cancer Res 60: 4873–4880.
42. Bais C, Santomasso B, Coso O, Arvanitakis L, Raaka E, et al. (1998) G-protein-
coupled receptor of Kaposi’s sarcoma-associated herpesvirus is a viral oncogene
and angiogenesis activator. Nature 391: 86–89.
43. Bais C, Van Geelen A, Eroles P, Mutlu A, Chiozzini C, et al. (2003) Kaposi’s
sarcoma associated herpesvirus G protein-coupled receptor immortalizes human
endothelial cells by activation of the VEGF receptor-2/KDR. Cancer Cell 3:
131–143.
44. Shan B, Morris CA, Zhuo Y, Shelby BD, Levy DR, et al. (2007) Activation of
proMMP-2 and Src by HHV8 vGPCR in human pulmonary arterial endothelial
cells. J Mol Cell Cardiol 42: 517–525.
45. Dourmishev L, Dourmishev A, Palmeri D, Schwartz R, Lukac D (2003)
Molecular genetics of Kaposi’s sarcoma-associated herpesvirus (human herpes-
virus-8) epidemiology and pathogenesis. Microbiol Mol Biol Rev 67: 175–212.
table of contents.
46. Murakami Y, Yamagoe S, Noguchi K, Takebe Y, Takahashi N, et al. (2006) Ets-
1-dependent expression of vascular endothelial growth factor receptors is
activated by latency-associated nuclear antigen of Kaposi’s sarcoma-associated
herpesvirus through interaction with Daxx. J Biol Chem 281: 28113–28121.
47. Mitra S, Schlaepfer D (2006) Integrin-regulated FAK-Src signaling in normal
and cancer cells. Curr Opin Cell Biol 18: 516–523.
48. Avraamides CJ, Garmy-Susini B, Varner JA (2008) Integrins in angiogenesis and
lymphangiogenesis. Nat Rev Cancer 8: 604–617.
49. Hehlgans S, Haase M, Cordes N (2007) Signalling via integrins: implications for
cell survival and anticancer strategies. Biochim Biophys Acta 1775: 163–180.
50. Gasparini G, Brooks PC, Biganzoli E, Vermeulen PB, Bonoldi E, et al. (1998)
Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer.
Clin Cancer Res 4: 2625–2634.
51. Bello L, Zhang J, Nikas DC, Strasser JF, Villani RM, et al. (2000) Alpha(v)beta3
and alpha(v)beta5 integrin expression in meningiomas. Neurosurgery 47:
1185–1195.
52. Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin
alpha v beta 3 for angiogenesis. Science 264: 569–571.
53. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, et al. (1994)
Integrin alpha v beta 3 antagonists promote tumor regression by inducing
apoptosis of angiogenic blood vessels. Cell 79: 1157–1164.
54. Brooks PC, Stro ¨mblad S, Klemke R, Visscher D, Sarkar FH, et al. (1995)
Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis
in human skin. J Clin Invest 96: 1815–1822.
55. Sheu JR, Yen MH, Kan YC, Hung WC, Chang PT, et al. (1997) Inhibition of
angiogenesis in vitro and in vivo: comparison of the relative activities of triflavin,
an Arg-Gly-Asp-containing peptide and anti-alpha(v)beta3 integrin monoclonal
antibody. Biochim Biophys Acta 1336: 445–454.
56. Garrigues HJ, Rubinchikova YE, Dipersio CM, Rose TM (2008) Integrin
alphaVbeta3 Binds to the RGD motif of glycoprotein B of Kaposi’s sarcoma-
associated herpesvirus and functions as an RGD-dependent entry receptor.
J Virol 82: 1570–1580.
57. Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, et al. (2009) An
integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence
and tumor progression. Nat Med 15: 1163–1169.
58. Dyson OF, Oxendine TL, Hamden KE, Ford PW, Akula SM (2008) Differential
regulation of the attachment of Kaposi’s sarcoma-associated herpesvirus
(KSHV)-infected human B cells to extracellular matrix by KSHV-encoded gB
and cellular alphaV integrins. Cell Microbiol 10: 1546–1558.
59. Dyson O, Bryan B, Lambert P, Ford P, Akula S (2007) Beta1 integrins mediate
tubule formation induced by supernatants derived from KSHV-infected cells.
Intervirology 50: 245–253.
60. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications
and therapeutic opportunities. Nat Rev Cancer 10: 9–22.
61. Mahabeleshwar GH, Feng W, Reddy K, Plow EF, Byzova TV (2007)
Mechanisms of integrin-vascular endothelial growth factor receptor cross-
activation in angiogenesis. Circ Res 101: 570–580.
62. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, et al. (2002)
Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and
beta5 integrins. Nat Med 8: 27–34.
63. Reynolds AR, Reynolds LE, Nagel TE, Lively JC, Robinson SD, et al. (2004)
Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates
enhanced angiogenesis in beta3-integrin-deficient mice. Cancer Res 64:
8643–8650.
64. Mahabeleshwar GH, Feng W, Phillips DR, Byzova TV (2006) Integrin signaling
is critical for pathological angiogenesis. J Exp Med 203: 2495–2507.
65. De S, Razorenova O, McCabe NP, O’Toole T, Qin J, et al. (2005) VEGF-
integrin interplay controls tumor growth and vascularization. Proc Natl Acad
Sci U S A 102: 7589–7594.
66. Nemerow G, Cheresh D (2002) Herpesvirus hijacks an integrin. Nat Cell Biol 4:
E69–71.
67. Veettil M, Sadagopan S, Sharma-Walia N, Wang F, Raghu H, et al. (2008)
Kaposi’s sarcoma-associated herpesvirus forms a multimolecular complex of
integrins (alphaVbeta5, alphaVbeta3, and alpha3beta1) and CD98-xCT during
infection of human dermal microvascular endothelial cells, and CD98-xCT is
essential for the postentry stage of infection. J Virol 82: 12126–12144.
68. Krishnan H, Sharma-Walia N, Streblow D, Naranatt P, Chandran B (2006)
Focal adhesion kinase is critical for entry of Kaposi’s sarcoma-associated
herpesvirus into target cells. J Virol 80: 1167–1180.
69. Sharma-Walia N, Naranatt P, Krishnan H, Zeng L, Chandran B (2004)
Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8 envelope glyco-
protein gB induces the integrin-dependent focal adhesion kinase-Src-phospha-
tidylinositol 3-kinase-rho GTPase signal pathways and cytoskeletal rearrange-
ments. J Virol 78: 4207–4223.
70. Wang F, Akula S, Sharma-Walia N, Zeng L, Chandran B (2003) Human
herpesvirus 8 envelope glycoprotein B mediates cell adhesion via its RGD
sequence. J Virol 77: 3131–3147.
71. Venetsanakos E, Mirza A, Fanton C, Romanov SR, Tlsty T, et al. (2002)
Induction of tubulogenesis in telomerase-immortalized human microvascular
endothelial cells by glioblastoma cells. Exp Cell Res 273: 21–33.
72. Renne R, Zhong W, Herndier B, McGrath M, Abbey N, et al. (1996) Lytic
growth of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in
culture. Nat Med 2: 342–346.
73. Chen L, Lagunoff M (2005) Establishment and maintenance of Kaposi’s
sarcoma-associated herpesvirus latency in B cells. J Virol 79: 14383–14391.
74. Rothermel T, Engelhardt B, Sheibani N (2005) Polyoma virus middle-T-
transformed PECAM-1 deficient mouse brain endothelial cells proliferate
rapidly in culture and form hemangiomas in mice. J Cell Physiol 202: 230–239.
KSHV Induces Integrin b3 to Activate Angiogenesis
PLoS Pathogens | www.plospathogens.org 12 December 2011 | Volume 7 | Issue 12 | e1002424